<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of diabetic kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of diabetic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of diabetic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vlado Perkovic, MBBS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunil V Badve, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) is common in people with both type 1 and type 2 diabetes. It is defined by the presence of reduced glomerular filtration rate (GFR) and/or increased urinary albumin excretion for at least three months  (<a class="graphic graphic_table graphicRef80632" href="/z/d/graphic/80632.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Definition of CKD'</a>.)</p><p>Classification and staging of CKD is based upon GFR and albuminuria  (<a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">table 2</a> and <a class="graphic graphic_figure graphicRef59716" href="/z/d/graphic/59716.html" rel="external">figure 1</a>). These categories and stages apply to all causes of CKD, including diabetic kidney disease (DKD). Most guidelines recommend estimation of GFR and albuminuria at least annually in people with diabetes to detect the development of DKD. (See  <a class="medical medical_review" href="/z/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Manifestations and case detection'</a>.)</p><p>Globally, DKD is a major cause of CKD and is the most common cause of end-stage kidney disease (ESKD). As an example, in the United States in 2017, diabetes was reported as a primary etiology in nearly one-half of all patients diagnosed with ESKD [<a href="#rid1">1</a>].</p><p>The management of individuals with DKD is discussed here  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>). The pathophysiology, epidemiology, natural history, evaluation, and diagnosis of DKD are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis"</a>.)</p><p></p><p>Other management issues in patients with diabetes are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H480197376"><span class="h1">MANAGEMENT OF DIABETIC KIDNEY DISEASE (DKD)</span></p><p class="headingAnchor" id="H3921119799"><span class="h2">General measures applicable to all patients with DKD</span><span class="headingEndMark"> — </span>The general approach to all people with diabetes is also appropriate for people with diabetic kidney disease (DKD), although there are some specific considerations  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2546317506"><span class="h3">Blood pressure control</span><span class="headingEndMark"> — </span>We recommend blood pressure lowering in patients with DKD to levels below 130/80 mmHg  (<a class="graphic graphic_table graphicRef117101" href="/z/d/graphic/117101.html" rel="external">table 3</a>). In general, this level of blood pressure control in patients with chronic kidney disease (CKD) reduces mortality and prevents cardiovascular morbidity. Additionally, intensive blood pressure lowering slows CKD progression among those with severely increased albuminuria (measured or estimated urine albumin excretion ≥300 mg/day). The evidence supporting our recommendation is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with chronic kidney disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a>.)</p><p></p><p>Initial antihypertensive therapy in patients with DKD typically consists of either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) titrated to maximally tolerated doses but not both simultaneously. The supporting data are discussed below and elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Severely increased albuminuria: Treat with angiotensin inhibition'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'</a>.)</p><p></p><p>Combination antihypertensive therapy is required for most individuals with DKD. In such cases, the combination of an ACE inhibitor or ARB plus a dihydropyridine calcium channel blocker is often preferred [<a href="#rid2">2</a>]; however, a nondihydropyridine calcium channel blocker or diuretic may be preferred, rather than a dihydropyridine calcium channel blocker, in patients with severely increased albuminuria. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Calcium channel blockers'</a>.)</p><p>As discussed in detail below, the combination of an ACE inhibitor plus an ARB should <strong>not</strong> be used. Similarly, simultaneous therapy with a renin inhibitor plus either an ACE inhibitor or ARB should be avoided. (See <a class="local">'Type 2 diabetes: Treat with additional kidney-protective therapy'</a> below.)</p><p class="headingAnchor" id="H1340578673"><span class="h3">Glycemic control</span><span class="headingEndMark"> — </span>In patients with type 1 diabetes, high-quality data suggest that intensive blood glucose control may prevent the development of DKD [<a href="#rid3">3,4</a>], and more limited data support the strategy of intensive glucose control in patients with kidney disease [<a href="#rid5">5,6</a>]. Consequently, the glycemic control target in patients with type 1 diabetes and DKD is ideally a glycated hemoglobin (A1C) of 7 percent or less, although the goal should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. However, glycemic targets in type 1 diabetes have not been well studied in patients with advanced CKD. The evidence for this approach is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a>.)</p><p>The approach (to target an A1C of 7 percent or less, if tolerated) is similar in patients with type 2 diabetes, although fewer supportive data are available than for type 1 diabetes [<a href="#rid7">7</a>]. Glycemic targets in patients with type 2 diabetes are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p>The risk of hypoglycemia with intensive glucose control is greater among patients with reduced glomerular filtration rate (GFR) [<a href="#rid8">8-10</a>]. This issue is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus"</a>.) </p><p>A separate issue is that certain glucose-lowering medications should be avoided or used at a reduced dose in patients with DKD, depending upon the degree of reduced kidney function [<a href="#rid11">11</a>]. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H4123555451"><span class="h3">Other</span><span class="headingEndMark"> — </span>In addition to blood pressure and glucose control, all patients with DKD should be counseled on lifestyle modification, and most should be treated with a statin:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle modification</strong> – Patients with diabetes, regardless of the presence of kidney disease, should be counseled on healthy eating, regular exercise, and if needed, weight loss and smoking cessation. (See  <a class="medical medical_review" href="/z/d/html/1766.html" rel="external">"Nutritional considerations in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1777.html" rel="external">"Exercise guidance in adults with diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipid lowering</strong> – Most patients with DKD are at high cardiovascular risk and should therefore be treated with a statin (<a class="calc calc_professional" href="/z/d/html/107063.html" rel="external">calculator 1</a>). If statin therapy is initiated in patients with reduced kidney function, <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> or <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a> are often preferred because they do not require dose adjustment based upon the GFR. However, statins have not been shown to reduce the risk of cardiovascular events or mortality in patients with ESKD and are not recommended in such patients. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Lipid management'</a> and  <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">"Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)", section on 'Lipid modification'</a>.)</p><p></p><p class="headingAnchor" id="H3561655732"><span class="h2">Severely increased albuminuria: Treat with angiotensin inhibition</span><span class="headingEndMark"> — </span>In addition to the general measures discussed above, we treat most patients who have diabetes and severely increased albuminuria with an ACE inhibitor <strong>or</strong> an ARB  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>). Severely increased albuminuria is defined as a measured (eg, with a 24-hour urine collection) or estimated (eg, using a random urine albumin-to-creatinine ratio [ACR]) albumin excretion ≥300 mg/day. Combination therapy with both an ACE inhibitor and an ARB, or combining one of these drugs with a renin inhibitor, should be <strong>avoided</strong>.</p><p>In practice, the majority of patients with diabetes with hypertension and DKD are treated with an ACE inhibitor or ARB, even if severely increased albuminuria is absent (ie, even if urine albumin excretion is &lt;300 mg/day). However, while these drugs are more beneficial than other antihypertensive agents in patients with albuminuric DKD, they do not have clear advantages over calcium channel blockers or diuretics among those without severely increased albuminuria. (See  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p>Inhibition of the renin-angiotensin system (RAS) has been the cornerstone of the management of DKD for decades. This is based on high-quality randomized trials demonstrating reductions in the risk of kidney outcomes in high-risk individuals:</p><p class="bulletIndent1"><span class="glyph">●</span>The best data supporting angiotensin inhibition in patients with type 1 diabetes come from a trial of 409 adult participants who had urine protein excretion ≥500 mg/day and a serum creatinine ≤2.5 mg/dL (221 micromol/L) [<a href="#rid12">12,13</a>]. Patients were randomly assigned to <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> (25 mg three times daily) or placebo; additional antihypertensive drugs were then added as necessary, although calcium channel blockers and other ACE inhibitors were excluded (ARBs were not available at the time of the trial). At three years, captopril reduced the rate of death or ESKD (11 versus 21 percent), reduced the likelihood of doubling of serum creatinine (12 versus 21 percent), and slowed the annual loss of creatinine clearance (11 versus 17 percent per year). The beneficial response to captopril, which was seen in both hypertensive and normotensive patients, is consistent with smaller studies that suggested that antihypertensive therapy with an ACE inhibitor slowed the rate of progression in diabetic nephropathy [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In type 2 diabetes, evidence comparing RAS inhibition with another antihypertensive drug comes from the <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">Irbesartan</a> Diabetic Nephropathy Trial (IDNT) [<a href="#rid16">16</a>]. In the IDNT, 1715 participants aged 30 to 70 years with type 2 diabetes, hypertension, urine protein excretion ≥0.9 g/day, and mean serum creatinine of 1.7 mg/dL (150 micromol/L) were randomly assigned to irbesartan (75 to 300 mg once daily), <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> (2.5 to 10 mg once daily), or placebo. Target systolic blood pressure was ≤135 mmHg, or 10 mmHg lower than the value at screening (if systolic blood pressure at screening ≥145 mmHg), and target diastolic blood pressure was ≤85 mmHg. At 2.6 years, the likelihood of a doubling of serum creatinine was lower with irbesartan (17 percent) compared with amlodipine (25 percent) and placebo (24 percent); in addition, irbesartan nonsignificantly reduced the incidence of ESKD (14 versus 18 percent with amlodipine and placebo)  (<a class="graphic graphic_figure graphicRef80116" href="/z/d/graphic/80116.html" rel="external">figure 2</a>). There was no difference among the groups with respect to cardiovascular endpoints or death. Patients assigned to placebo had a higher blood pressure throughout the trial than those assigned irbesartan; however, the blood pressure in the irbesartan and amlodipine groups were similar, and therefore the benefits from irbesartan were independent of attained blood pressure [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">Losartan</a> (RENAAL) trial assigned 1513 adults with type 2 diabetes, albuminuria &gt;300 mg/day (median urinary ACR of approximately 1250 mg/g), and mean serum creatinine 1.9 mg/dL (168 micromol/L), to losartan (50 titrating up to 100 mg once daily) or placebo, both in addition to conventional antihypertensive therapy (but not ACE inhibitors) [<a href="#rid19">19</a>]. The incidence of ESKD at 3.4 years was lower with losartan (20 versus 26 percent), as was a doubling of serum creatinine (22 versus 26 percent). Unlike IDNT, there was no active comparator, and the mean blood pressure throughout the study was lower among those assigned losartan.</p><p></p><p>The three trials cited above enrolled patients with albuminuric DKD (measured or estimated urine albumin excretion ≥300 mg/day). Several large trials suggest that angiotensin inhibition decreases the risk of progression from normal-to-mildly increased albuminuria (formerly called "normoalbuminuria") to moderately increased albuminuria (formerly called "microalbuminuria") and from moderately increased albuminuria to severely increased albuminuria (formerly called "macroalbuminuria") [<a href="#rid20">20,21</a>]. However, no major trial has found that these drugs prevent ESKD among patients with nonalbuminuric DKD, particularly when compared with a different antihypertensive drug (ie, an active comparator). As an example, in the largest antihypertensive drug trial among patients with diabetes, over 11,000 patients with type 2 diabetes were randomly assigned to a two-drug antihypertensive combination (<a class="drug drug_general" data-topicid="9758" href="/z/d/drug information/9758.html" rel="external">perindopril</a> plus <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">indapamide</a>) or placebo [<a href="#rid21">21</a>]. The mean blood pressure during the trial in the active treatment group was 6/2 mmHg lower than in the placebo group, and it is not possible to determine the degree to which the reduction in albuminuria was due to the ACE inhibitor, thiazide-like diuretic, or lower blood pressure [<a href="#rid22">22,23</a>].</p><p>There are no proven differences in outcomes comparing ACE inhibitors with ARBs in trials among patients with diabetes or among broader populations [<a href="#rid24">24-26</a>]. Thus, in general, either agent can be used when treating patients with DKD.</p><p>However, although combining an ACE inhibitor and an ARB decreases albuminuria compared with either agent alone, combination therapy does <strong>not</strong> prevent kidney disease progression or death, and it increases the rate of serious adverse events. Combination therapy with an ACE inhibitor plus an ARB should therefore <strong>not</strong> be used in patients with DKD:</p><p class="bulletIndent1"><span class="glyph">●</span>The best data come from the Veterans Affairs Nephropathy in Diabetes study (VA NEPHRON-D), a randomized placebo-controlled double-blind trial performed in 1448 mostly male patients with diabetic nephropathy (mean estimated GFR [eGFR], 54 mL/min/1.73 m<sup>2</sup>; mean ACR, 852 mg/g) [<a href="#rid27">27</a>]. All patients received 100 mg/day of <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> and were then randomly assigned to placebo or <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> (10 to 40 mg/day as tolerated); the primary endpoint was a composite of a 50 percent eGFR decline (or more than 30 mL/min/1.73 m<sup>2</sup>), ESKD, or death. The trial was discontinued early after a median of 2.2 years because of safety concerns. The combination therapy and monotherapy groups had a similar rate of primary events (18.2 versus 21 percent). However, acute kidney injury requiring hospitalization or occurring during hospitalization was significantly more common with combination therapy (18 versus 11 percent), as was severe hyperkalemia (9.9 versus 4.4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data come from the diabetes subgroup of the Ongoing <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">Telmisartan</a> Alone and in Combination with <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">Ramipril</a> Global Endpoint Trial (ONTARGET). The ONTARGET trial compared combination ramipril and telmisartan therapy with ramipril alone in 25,620 patients with vascular disease or diabetes [<a href="#rid25">25,26</a>]. In the subset of 3163 patients from ONTARGET with DKD, combination therapy was associated with a nonsignificantly higher incidence of ESKD or doubling of serum creatinine (5.3 versus 4.8 percent), and a similar death rate (2.3 versus 2.2 percent), as compared with monotherapy [<a href="#rid28">28</a>]. In addition, patients with DKD who received combination therapy had higher rates of acute kidney injury requiring dialysis (1.4 versus 0.8 percent). Other findings from the ONTARGET trial are presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Combination of ACE inhibitors and ARBs'</a> and  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p></p><p>Similarly, the use of <a class="drug drug_general" data-topicid="9282" href="/z/d/drug information/9282.html" rel="external">aliskiren</a>, a direct renin inhibitor, in combination with either an ACE inhibitor or ARB does <strong>not</strong> appear to preserve kidney function, and it increases the risk of adverse events [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2546483452"><span class="h2">Type 2 diabetes: Treat with additional kidney-protective therapy</span><span class="headingEndMark"> — </span>In addition to the general measures discussed above plus the use of an ACE inhibitor (or ARB) in albuminuric patients, patients with type 2 diabetes and DKD should be treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors. </p><p>Among patients with type 2 diabetes who have measured or estimated albuminuria ≥30 mg/day despite an ACE inhibitor (or ARB) and an SGLT2 inhibitor (or if an SGLT2 inhibitor is not tolerated), we suggest treatment with a nonsteroidal selective mineralocorticoid receptor antagonist (MRA; specifically <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a>), where available, provided the patient has a serum potassium ≤5 mEq/L and eGFR ≥25 mL/min/1.73 m<sup>2</sup> (see <a class="local">'General measures applicable to all patients with DKD'</a> above and <a class="local">'Severely increased albuminuria: Treat with angiotensin inhibition'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>SGLT2 inhibitors – We recommend treatment of most patients with type 2 diabetes and DKD with an SGLT2 inhibitor, regardless of the degree of glycemic control  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>) [<a href="#rid30">30,31</a>]. Initiating SGLT2 inhibitors should generally be avoided among patients with an eGFR &lt;20 mL/min/1.73 m<sup>2</sup> although they can likely be continued safely among patients whose eGFR ultimately falls below 20 mL/min/1.73 m<sup>2</sup> [<a href="#rid32">32</a>]. If <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a> is used, the dose is 100 mg once daily. If <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> is used, the dose is 10 mg once daily.</p><p></p><p class="bulletIndent1">SGLT2 inhibitors can prevent important kidney endpoints, including ESKD [<a href="#rid31">31,33</a>]. Although the relative risk reduction of kidney failure is similar among patients with and without severely increased albuminuria (measured or estimated urine albumin excretion ≥300 mg/day), the absolute risk reduction is greater among those with severely increased albuminuria, since such patients have a higher absolute risk of developing a major kidney event. Thus, our recommendation is stronger for those with severely increased albuminuria than for those with normoalbuminuria or moderately increased albuminuria. The rationale for our approach is presented in detail below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal selective MRAs – Among patients with type 2 diabetes who have measured or estimated albuminuria ≥30 mg/day despite an ACE inhibitor (or ARB) and an SGLT2 inhibitor (or if an SGLT2 inhibitor is not tolerated), we suggest treatment with a nonsteroidal selective MRA, specifically <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a>, where available, provided the patient has a serum potassium ≤5 mEq/L and eGFR ≥25 mL/min/1.73 m<sup>2</sup>. The starting dose of finerenone is 20 mg once daily if eGFR is ≥60 mL/min/1.73 m<sup>2</sup> and 10 mg once daily if eGFR is ≥25 to 60 mL/min/1.73 m<sup>2</sup>. The serum potassium and creatinine should be measured four weeks after starting finerenone. If the starting dose was 10 mg once daily, the dose can be increased to 20 mg once daily four weeks later if serum potassium is ≤4.8 mEq/L and eGFR has not declined by more than 30 percent.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">Finerenone</a> reduces the progression of kidney function impairment and cardiovascular events in patients with type 2 diabetes and DKD, while not substantially impacting blood pressure and only slightly increasing serum potassium levels. Finerenone has been studied in patients taking maximally tolerated doses of ACE inhibitors or ARBs but has not been studied extensively in patients taking SGLT2 inhibitors plus maximally tolerated doses of ACE inhibitors or ARBs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucagon-like peptide 1 (GLP-1) receptor agonists – SGLT2 inhibitors have a weak glucose-lowering effect, particularly in patients with reduced eGFR, and therefore patients whose glycated hemoglobin is far from their goal are likely to require additional glucose-lowering therapy. Aside from SGLT2 inhibitors, the glucose-lowering drugs with the strongest evidence of benefit on cardiovascular and kidney outcomes in patients with preexisting cardiovascular or kidney disease are the GLP-1 receptor agonists [<a href="#rid31">31</a>]. Thus, in patients with type 2 diabetes and DKD who have not achieved glycemic control despite initial glucose-lowering therapy (which is typically <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>) and an SGLT2 inhibitor, a GLP-1 receptor agonist can improve glycemic control and <strong>may </strong>provide additional benefit [<a href="#rid34">34-36</a>]. GLP-1 receptor agonists are discussed below and in other topics. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p>Our recommendations outlined above are consistent with guidelines from the American Diabetes Association (ADA) and the Kidney Disease Improving Global Outcomes (KDIGO) on the treatment of patients with DKD [<a href="#rid37">37,38</a>]. </p><p>Among those with an eGFR &gt;45 mL/min/1.73 m<sup>2</sup>, SGLT2 inhibitors act by blocking reabsorption of glucose in the proximal tubule through SGLT2, which lowers the renal glucose threshold and leads to substantial glycosuria. The glycosuria is dependent upon kidney function, and therefore the magnitude of glycosuria and lowering of blood glucose is smaller among individuals with reduced kidney function.</p><p>SGLT2 inhibitors have additional effects on the kidney, and, given their weak glucose-lowering effect, these effects are likely independent of glycemic control. By blocking the cotransporter, they reduce sodium reabsorption, which is usually increased in patients with diabetes due to the excess tubular glucose load. The resulting natriuresis reduces intravascular volume and blood pressure, but it also increases the delivery of sodium to the macula densa. Increased sodium delivery to the macula densa normalizes tubuloglomerular feedback and thereby reduces intraglomerular pressure (ie, reduces glomerular hyperfiltration) through constriction of the abnormally dilated afferent arteriole [<a href="#rid39">39</a>]. This decrease in glomerular hyperfiltration can, hypothetically, slow the rate of progression of kidney disease (see  <a class="medical medical_review" href="/z/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology", section on 'Glomerular hyperfiltration'</a>). A range of additional mechanisms may explain the benefits of SGLT2 inhibitors on kidney disease progression [<a href="#rid40">40</a>].</p><p>SGLT2 inhibitors reduce the risk of kidney disease progression among patients with DKD who are already taking ACE inhibitors (or ARBs) [<a href="#rid33">33,41-47</a>], as well as the incidence of cardiovascular disease [<a href="#rid33">33</a>]. Among patients with DKD and severely increased albuminuria, the best data come from three large trials:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">Canagliflozin</a> and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial compared canagliflozin (100 mg once daily) with placebo in 4401 diabetic patients with an eGFR between 30 and 89 mL/min/1.73 m<sup>2</sup> and urine ACR &gt;300 mg/g (median, 927 mg/g) despite taking an ACE inhibitor or ARB [<a href="#rid42">42</a>]. At 2.6 years, canagliflozin reduced the incidence of ESKD (5.3 versus 7.5 percent), doubling of serum creatinine (5.4 versus 8.5 percent), hospitalization for heart failure (4.0 versus 6.4 percent), cardiovascular death (5.0 versus 6.4 percent), and all-cause mortality (7.6 versus 9.1 percent), although the effects on cardiovascular death and all-cause mortality were not separately statistically significant. The beneficial effects of canagliflozin on slowing kidney function decline appeared to be similar among those with baseline eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (ie, among trial participants whose eGFR fell to below 30 mL/min/1.73 m<sup>2</sup> between enrollment and initiation of study medication) [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the similarly designed <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">Dapagliflozin</a> and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, 4304 individuals with eGFR 25 to 75 mL/min/1.73 m<sup>2</sup> and urine ACR 200 to 5000 mg/g (median 950 mg/g) were randomly assigned to dapagliflozin (10 mg once daily) or placebo [<a href="#rid49">49</a>]. Approximately two-thirds of enrolled patients had type 2 diabetes; 98 percent were taking an ACE inhibitor or ARB. At 2.4 years, dapagliflozin reduced all-cause mortality (4.7 versus 6.8 percent), as well as the incidence of ESKD (5.1 versus 7.5 percent), and also reduced the risk of a 50 percent or greater decline in eGFR (5.2 versus 9.3 percent). The beneficial effect of dapagliflozin was similar in patients with DKD and in patients with other forms of kidney disease, reinforcing the concept that beneficial effects are independent of glycemic control. There were no differences between the treatment groups with respect to major adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Study of Heart and Kidney Protection with <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">Empagliflozin</a> (EMPA-KIDNEY) trial, 6609 patients with eGFR 20 to 44 mL/min/1.73 m<sup>2</sup> (regardless of albuminuria) or 45 to 89 mL/min/1.73 m<sup>2</sup> (if albumin-to-creatinine ratio was at least 200 mg/g) were randomly assigned to empagliflozin 10 mg daily or placebo [<a href="#rid50">50</a>]. Less than half (46 percent) of participants had diabetes. At two years, empagliflozin reduced the incidence of ESKD (3.3 versus 4.8 percent), the incidence of a sustained decline in eGFR to &lt;10 mL/min/1.73 m<sup>2</sup> (3.5 versus 5.1 percent), and the incidence of a sustained decrease in eGFR of 40 percent or more (10.9 versus 14.3 percent). The risks of all-cause mortality (4.5 versus 5.1 percent) and nonfatal cardiovascular events (4.3 versus 4.6 percent) were similar between the groups. Effects were similar in patients with and without diabetes and regardless of the eGFR at the start of the study. The benefit from empagliflozin was larger in patients with albumin-to-creatinine ratio ≥300 mg/g and substantially less in patients with lower albumin excretion. </p><p></p><p>Numerous other large trials of SGLT2 inhibitors in patients with type 2 diabetes enrolled subsets of patients with mostly nonalbuminuric DKD [<a href="#rid45">45,51-61</a>]. A meta-analysis of 13 trials and more than 90,000 participants with and without preexisting CKD (including the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials) examined the effect of SGLT2 inhibitors on kidney disease progression, which was defined as a sustained 50 percent or greater decline in eGFR, need for maintenance dialysis, kidney transplantation, or a sustained decline in eGFR to &lt;10 to 15 mL/min/1.73 m<sup>2</sup> [<a href="#rid51">51</a>]. Compared with placebo, SGLT2 inhibitors reduced the rate of kidney disease progression among patients with diabetes regardless of preexisting DKD (1.8 versus 3.8 percent; hazard ratio [HR] 0.62, 95% CI 0.56-0.68). Among those with preexisting DKD, SGLT2 inhibitors lowered the rate of kidney failure (defined as the need for maintenance dialysis, kidney transplantation, or a sustained decline in eGFR to &lt;10 to 15 mL/min/1.73 m<sup>2</sup>) compared with placebo (5.2 versus 7.6 percent; HR 0.66, 95% CI 0.56-0.77). </p><p>The relative benefits from SGLT2 inhibitors were similar among patients with different baseline levels of albumin excretion. However, given that the rate of kidney disease progression is substantially higher in patients with severely increased albuminuria, the absolute benefits of SGLT2 inhibitor therapy are greater among those with higher levels of albuminuria, despite similar relative risks.</p><p>SLGT2 inhibitors also reduced the rates of major cardiovascular events among patients with established atherosclerotic cardiovascular disease regardless of whether patients had DKD [<a href="#rid31">31,33,45,51,56,59</a>]. These drugs also prevent heart failure hospitalization and death in patients who have heart failure with reduced ejection fraction. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Clinical outcomes'</a>.)</p><p>SGLT2 inhibitors increase the risk of genital infections by two- to fourfold; such infections primarily include vulvovaginal candidiasis, which occur in 10 to 15 percent of women taking these drugs. SGLT2 inhibitors are also associated with Fournier's gangrene in rare cases [<a href="#rid62">62</a>]. In addition, SGLT2 inhibitors can produce "euglycemic" diabetic ketoacidosis in type 1 diabetes (and more rarely in type 2 diabetes). Thus, patients with a prior history of or risk factors for genital infections may reasonably choose to not take an SGLT2 inhibitor. In patients with DKD who have a lower absolute risk for progression of kidney disease, and who also do not have established atherosclerotic cardiovascular disease or heart failure, the benefits and harms of taking an SGLT2 inhibitor may be more closely balanced. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Adverse effects'</a>.)</p><p>Activation of the mineralocorticoid receptor is associated with cardiovascular and kidney disease, putatively by stimulating inflammatory and fibrotic cascades [<a href="#rid63">63</a>]. Steroidal MRAs, such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, reduce albuminuria in patients with DKD but often cause hyperkalemia in patients with reduced eGFR, particularly when ACE inhibitors or ARBs are also used. The nonsteroidal MRA <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a> also reduces albuminuria and has a smaller effect on the serum potassium [<a href="#rid64">64,65</a>]. The effects of finerenone on kidney disease progression were examined in two large trials: </p><p class="bulletIndent1"><span class="glyph">●</span>In the <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">Finerenone</a> in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, 5734 patients with type 2 diabetes and either severely increased albuminuria or moderately increased albuminuria plus retinopathy were randomly assigned to finerenone (10 to 20 mg once daily) or placebo [<a href="#rid66">66</a>]. All patients were taking a maximal, or maximally tolerated, dose of an ACE inhibitor or ARB at baseline. At 2.6 years, finerenone decreased the incidence of a 40 percent or larger decline in eGFR (16.9 versus 20.3 percent) and nonsignificantly reduced the rates of all-cause mortality (7.7 versus 8.6 percent), and kidney failure (7.3 versus 8.3 percent), which included an eGFR &lt;15 mL/min/1.73 m<sup>2</sup> or the need for chronic dialysis. Hyperkalemia occurred more frequently with finerenone (18.3 versus 9.0 percent), although only a small number of patients discontinued randomized therapy due to this complication (2.3 versus 0.9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar trial tested the effects of <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a> in 7437 patients with diabetic kidney disease who had less severe kidney disease (moderately increased albuminuria with an eGFR 25 to 90 mL/min/1.73 m<sup>2</sup> or severely increased albuminuria with an eGFR &gt;60 mL/min/1.73 m<sup>2</sup>) [<a href="#rid67">67</a>]. Compared with placebo, finerenone reduced the risk of heart failure hospitalization (3.2 versus 4.4 percent), and nonsignificantly lowered the rate of kidney failure (1.2 versus 1.7 percent) and all-cause mortality (9.0 versus 10.1 percent). Hyperkalemia was more common with finerenone (10.8 versus 5.3 percent). </p><p></p><p>In a pooled analysis of these two trials, <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a> lowered the risk of kidney failure (3.9 versus 4.6 percent; HR 0.84, 95% CI 0.71-0.99) and hospitalization for heart failure (3.9 versus 5.0 percent; HR 0.78, 95% CI 0.66-0.92) at a median of three years, and nonsignificantly reduced all-cause mortality (8.5 versus 9.4 percent; HR 0.89, 95% CI 0.79-1.00) [<a href="#rid68">68</a>]. </p><p>The great majority of patients enrolled in these two trials were <strong>not</strong> simultaneously treated with an SGLT2 inhibitor, and the subgroup of patients who were was too small to determine with certainty whether or not <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a> provided additional benefit.</p><p>Another nonsteroidal MRA, esaxerenone, also reduces albuminuria in patients with DKD [<a href="#rid69">69</a>]. However, trials of esaxerenone report higher rates of hyperkalemia than those examining <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a> [<a href="#rid69">69-71</a>], and the effects of esaxerenone on mortality and ESKD are unknown.</p><p>The GLP-1 receptor agonist <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> reduced the incidence of a composite kidney endpoint (consisting of new onset of albuminuria &gt;300 mg/day, doubling of serum creatinine, ESKD, or kidney death) in a large trial of patients with type 2 diabetes [<a href="#rid72">72</a>]. However, the effect was predominantly due to a reduction in new-onset albuminuria. Similarly, another GLP-1 receptor agonist <a class="drug drug_general" data-topicid="97148" href="/z/d/drug information/97148.html" rel="external">dulaglutide</a> slowed the rate of decline in eGFR and prevented worsening of albuminuria in trials of patients with type 2 diabetes with and without CKD [<a href="#rid73">73,74</a>]. Thus, if additional glucose-lowering therapy is required in a patient with DKD despite initial glucose-lowering therapy and an SGLT2 inhibitor, then we would prefer starting a GLP-1 receptor agonist. GLP-1 receptor agonists also reduce the rates of cardiovascular disease [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Microvascular outcomes'</a> and  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p>By inhibiting dipeptidyl peptidase (DPP) 4, DPP-4 inhibitors prevent the deactivation of a variety of bioactive peptides, including GLP-1, thereby modestly increasing GLP-1 levels. However, unlike GLP-1 receptor agonists, DPP-4 inhibitors have not prevented the development or progression of kidney disease in patients with diabetes, nor do they have any cardiovascular benefits [<a href="#rid75">75,76</a>]. The use of DPP-4 inhibitors in patients with type 2 diabetes, including their safety and need for dose adjustments in the setting of CKD, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus"</a>.)</p><p>A large trial of more than 5000 individuals with type 2 diabetes treated with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> monotherapy directly compared the kidney effects of the GLP-1 receptor agonist <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> with a DDP-4 inhibitor, insulin, and <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">glimepiride</a> [<a href="#rid77">77</a>]. There were no significant differences among the groups at five years in terms of eGFR decline or development of CKD in this low-risk group. The patients enrolled had normal kidney function and well controlled blood pressure at baseline, and the number of events was small. As an example, despite the large study population, only 65 patients had a decline in kidney function of more than 40 percent to an eGFR &lt;60 mL/min/1.73m<sup>2</sup>. This study does not support the use of expensive GLP-1 receptor agonists for kidney protection in patients at low risk.</p><p class="headingAnchor" id="H2890825753"><span class="h2">Therapies of limited use</span><span class="headingEndMark"> — </span>Various other approaches have been studied as methods to slow the progression of DKD. However, there are insufficient data to advocate their use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary protein restriction</strong> – The role of dietary protein restriction is unclear in patients with diabetes, particularly since such patients are often being treated with fat and simple carbohydrate restriction. Data are conflicting as to whether protein restriction can slow the progression of kidney disease [<a href="#rid78">78-80</a>]. In addition, it is uncertain whether a low-protein diet is significantly additive to other measures aimed at preserving kidney function, such as ACE inhibition and aggressive control of blood pressure and blood glucose [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications and supplements</strong> – Other agents, some experimental and others in clinical use for other indications, have also been studied, including endothelin receptor antagonists, bardoxolone methyl, <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, protein kinase C inhibitors, <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">fenofibrate</a> (a peroxisome proliferator-activated receptor [PPAR]-alpha specific ligand), silymarin (an herbal drug with antioxidant properties used in patients with hepatic disease), Janus kinase (JAK) 1 and 2 inhibitors, and fish oil [<a href="#rid81">81-99</a>].</p><p></p><p class="headingAnchor" id="H2744894137"><span class="h1">MONITORING DURING THERAPY</span><span class="headingEndMark"> — </span>Patients with diabetic kidney disease (DKD) should ideally be monitored every three to six months, with assessments of blood pressure, volume status, estimated glomerular filtration rate (eGFR) based on serum creatinine, serum potassium, glycated hemoglobin (A1C), and an evaluation of urine albumin or total protein excretion (usually a random urine albumin-to-creatinine ratio [ACR]). Other aspects of monitoring should be based upon the clinical situation. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p>In addition, it is prudent to assess the serum creatinine and potassium within one to two weeks of starting or intensifying renin-angiotensin system (RAS) inhibition [<a href="#rid100">100</a>]. Blood pressure should be assessed within one to two weeks of initiating or intensifying these agents.</p><p>An elevation in serum creatinine of as much as 30 to 35 percent above baseline that stabilizes within the first two to four months of therapy is considered acceptable and <strong>not</strong> a reason to discontinue therapy with these drugs [<a href="#rid101">101-107</a>]. In addition, among patients who are on chronic treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), the drug does not need to be discontinued if the eGFR declines to below 30 mL/min/1.73 m<sup>2</sup> [<a href="#rid108">108</a>].</p><p>Modest hyperkalemia should generally be managed, if possible, without reducing or discontinuing the ACE inhibitor, ARB, or <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a>, unless there is another reason to do so. If discontinued for hyperkalemia, the ACE inhibitor or ARB should be resumed as soon as it is safe to do so. Finerenone can be resumed if serum potassium is ≤5 mEq/L at a dose of 10 mg once daily, and the dose can be increased to 20 mg once daily if serum potassium, four weeks later, is ≤4.8 mEq/L. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Patients who can have the serum potassium lowered slowly'</a>.)</p><p>Similarly, the serum creatinine, serum potassium, and blood pressure, plus the patient's volume status, should generally be ascertained within a few weeks of commencing a sodium-glucose cotransporter 2 (SGLT2) inhibitor. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Hypotension'</a>.)</p><p>Both RAS inhibition and SGLT2 inhibitors may increase the risk of symptomatic hypotension, and other antihypertensive therapies should be withdrawn first (if possible) before considering cessation of these evidence-based therapies. Similarly, SGLT2 inhibitors may cause volume depletion, and withdrawal or reduction of thiazide or loop diuretics should be attempted before discontinuing the SGLT2 inhibitor.</p><p>Reasons for referral of patients with DKD to a specialist nephrology service are similar to those for patients with other causes of chronic kidney disease (CKD), including advanced CKD (eGFR &lt;30 mL/min/1.73m<sup>2</sup>), heavy albuminuria, rapid loss of kidney function, resistant hypertension, evidence of an inflammatory kidney disease (eg, hematuria and/or sterile pyuria), and difficult-to-manage complications of CKD (eg, hyperkalemia, anemia). (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Referral to a specialist'</a>.)</p><p class="headingAnchor" id="H2715761590"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>A substantial proportion of people with diabetic kidney disease (DKD) will have progressive loss of kidney function and will develop end-stage kidney disease (ESKD). The strongest risk factor for risk of progression is the presence of increased albuminuria, while people with reduced estimated glomerular filtration rate (eGFR) or anemia are also at increased risk. With available protective therapies, a dramatic stabilization of kidney function is likely to be achievable. (See  <a class="medical medical_review" href="/z/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Natural history'</a>.)</p><p>Of note, people with DKD are at particularly high risk of cardiovascular events, and most have a higher risk of death (mostly cardiovascular) than developing kidney failure. Cardiovascular protective therapies are therefore also critical. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Reducing the risk of macrovascular disease'</a>.)</p><p class="headingAnchor" id="H4009772895"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H1223409836"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4428.html" rel="external">"Patient education: Diabetic kidney disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H283309083"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The general approach to all people with diabetes is also appropriate for people with diabetic kidney disease (DKD); specific considerations include  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>) (see <a class="local">'General measures applicable to all patients with DKD'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intensive blood pressure lowering is appropriate in patients with DKD  (<a class="graphic graphic_table graphicRef117101" href="/z/d/graphic/117101.html" rel="external">table 3</a>). The evidence supporting our recommendation is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a> and <a class="local">'Blood pressure control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The glycemic control target in patients with type 1 diabetes and DKD is ideally a glycated hemoglobin (A1C) of 7 percent or less, although the goal should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. However, glycemic targets in type 1 diabetes have not been well studied in patients with advanced chronic kidney disease (CKD). The approach (to target an A1C of 7 percent or less, if tolerated) is similar in patients with type 2 diabetes, although fewer supportive data are available than for type 1 diabetes. The evidence for these approaches is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a> and <a class="local">'Glycemic control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition to blood pressure and glucose control, all patients with DKD should be counseled on lifestyle modification and most should be treated with a statin. (See <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with type 1 or type 2 diabetes who have DKD and severely increased albuminuria, we recommend an antihypertensive regimen that includes an angiotensin-converting enzyme (ACE) inhibitor <strong>or</strong> an angiotensin receptor blocker (ARB) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>). Severely increased albuminuria is defined as a measured (eg, with a 24 hour-urine collection) or estimated (eg, using a random urine albumin-to-creatinine ratio [ACR]) albumin excretion ≥300 mg/day. In practice, the majority of patients with diabetes with hypertension and DKD are treated with an ACE inhibitor or ARB, even if severely increased albuminuria is absent (ie, even if urine albumin excretion is &lt;300 mg/day). However, while these drugs are more beneficial than other antihypertensive agents in patients with albuminuric DKD, they do not have clear advantages over calcium channel blockers or diuretics among those without albuminuria. (See <a class="local">'Severely increased albuminuria: Treat with angiotensin inhibition'</a> above.)</p><p></p><p class="bulletIndent1">Combination therapy with both an ACE inhibitor and an ARB, or combining one of these drugs with a renin inhibitor, should be <strong>avoided</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with type 2 diabetes who have DKD and severely increased albuminuria (as defined above) despite angiotensin inhibition, we recommend treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>)  (<a class="graphic graphic_algorithm graphicRef123083" href="/z/d/graphic/123083.html" rel="external">algorithm 1</a>). We also suggest use of an SGLT2 inhibitor in patients with DKD who have lower levels of urine albumin excretion (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The SGLT2 inhibitor is typically added to the patient's existing glucose-lowering regimen since these drugs have weak glucose-lowering effects in patients with reduced kidney function. (See <a class="local">'Type 2 diabetes: Treat with additional kidney-protective therapy'</a> above.)</p><p></p><p class="bulletIndent1">Initiating SGLT2 inhibitors should generally be avoided among patients with an estimated glomerular filtration rate (eGFR) &lt;20 mL/min/1.73 m<sup>2</sup> (although they can likely be continued among patients whose eGFR ultimately falls below this threshold).</p><p></p><p class="bulletIndent1">SGLT2 inhibitors increase the risk of genital infections by two- to fourfold (primarily vulvovaginal candidiasis) and have been associated with Fournier's gangrene in rare cases. Thus, patients with a prior history of or risk factors for genital infections may reasonably choose to not take an SGLT2 inhibitor.</p><p></p><p class="bulletIndent1">SGLT2 inhibitors are not appropriate for use in patients with type 1 diabetes and kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with type 2 diabetes who have measured or estimated albuminuria ≥30 mg/day despite an ACE inhibitor (or ARB) and an SGLT2 inhibitor (or if an SGLT2 inhibitor is not tolerated), we suggest treatment with a nonsteroidal selective mineralocorticoid receptor antagonist (MRA; specifically <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">finerenone</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), where available. However, finerenone should generally be avoided in patients who have a serum potassium &gt;5 mEq/L or eGFR&lt;25 mL/min/1.73 m<sup>2</sup>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Besides SGLT2 inhibitors (which have a weak glucose-lowering effect, particularly in patients with reduced eGFR), the glucose-lowering drugs with the strongest evidence of benefit on cardiovascular and kidney outcomes are the glucagon-like peptide 1 (GLP-1) receptor agonists. (See <a class="local">'Type 2 diabetes: Treat with additional kidney-protective therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with DKD should ideally be monitored every three to six months, with assessments of blood pressure, volume status, eGFR, serum potassium, and A1C, and an evaluation of urine albumin or total protein excretion (usually a random urine ACR). Reasons for referral of patients with DKD to a specialist nephrology service are similar to those for patients with other causes of CKD, including advanced CKD (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>), heavy albuminuria, rapid loss of kidney function, resistant hypertension, evidence of an inflammatory kidney disease (eg, hematuria and/or sterile pyuria), and difficult-to-manage complications of CKD (eg, hyperkalemia, anemia). (See <a class="local">'Monitoring during therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://www.usrds.org/reference.aspx (Accessed on March 05, 2020).</li><li><a class="nounderline abstract_t">Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.</a></li><li><a class="nounderline abstract_t">DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366.</a></li><li><a class="nounderline abstract_t">Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; :CD009122.</a></li><li><a class="nounderline abstract_t">Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.</a></li><li><a class="nounderline abstract_t">Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47:1703.</a></li><li><a class="nounderline abstract_t">Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; :CD008143.</a></li><li><a class="nounderline abstract_t">Amod A, Buse JB, McGuire DK, et al. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Ther 2020; 11:53.</a></li><li><a class="nounderline abstract_t">Davis TM, Brown SG, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010; 95:2240.</a></li><li><a class="nounderline abstract_t">Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc 2014; 89:1564.</a></li><li><a class="nounderline abstract_t">Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013; 9:147.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.</a></li><li><a class="nounderline abstract_t">Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994; 46:1688.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129.</a></li><li><a class="nounderline abstract_t">Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60:228.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851.</a></li><li><a class="nounderline abstract_t">Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170.</a></li><li><a class="nounderline abstract_t">Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16:3027.</a></li><li><a class="nounderline abstract_t">Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.</a></li><li><a class="nounderline abstract_t">Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870.</a></li><li><a class="nounderline abstract_t">Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829.</a></li><li><a class="nounderline abstract_t">Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Lancet 2007; 370:804.</a></li><li><a class="nounderline abstract_t">Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med 2008; 148:400.</a></li><li><a class="nounderline abstract_t">Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952.</a></li><li><a class="nounderline abstract_t">ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.</a></li><li><a class="nounderline abstract_t">Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.</a></li><li><a class="nounderline abstract_t">Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892.</a></li><li><a class="nounderline abstract_t">Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013; 31:414.</a></li><li><a class="nounderline abstract_t">Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43:S135.</a></li><li><a class="nounderline abstract_t">Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372:m4573.</a></li><li><a class="nounderline abstract_t">Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant 2018; 33:2005.</a></li><li><a class="nounderline abstract_t">Salah HM, Al'Aref SJ, Khan MS, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J 2021; 232:10.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med 2021; 385:896.</a></li><li><a class="nounderline abstract_t">Dave CV, Kim SC, Goldfine AB, et al. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation 2021; 143:770.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98:S1.</a></li><li><a class="nounderline abstract_t">de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2022; 102:974.</a></li><li><a class="nounderline abstract_t">Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102:990.</a></li><li><a class="nounderline abstract_t">Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016; 134:752.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94:26.</a></li><li><a class="nounderline abstract_t">Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7:845.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393:31.</a></li><li><a class="nounderline abstract_t">Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol 2017; 28:368.</a></li><li><a class="nounderline abstract_t">Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375:323.</a></li><li><a class="nounderline abstract_t">Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29:2755.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2021; 384:129.</a></li><li><a class="nounderline abstract_t">Bakris G, Oshima M, Mahaffey KW, et al. Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol 2020; 15:1705.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:1436.</a></li><li><a class="nounderline abstract_t">The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388:117.</a></li><li><a class="nounderline abstract_t">Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400:1788.</a></li><li><a class="nounderline abstract_t">Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014; 13:102.</a></li><li><a class="nounderline abstract_t">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 2013; 166:217.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19:387.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644.</a></li><li><a class="nounderline abstract_t">Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6:691.</a></li><li><a class="nounderline abstract_t">Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation 2018; 138:458.</a></li><li><a class="nounderline abstract_t">Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7:606.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347.</a></li><li><a class="nounderline abstract_t">Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383:1413.</a></li><li><a class="nounderline abstract_t">Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med 2019; 170:764.</a></li><li><a class="nounderline abstract_t">Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96:302.</a></li><li><a class="nounderline abstract_t">Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42:152.</a></li><li><a class="nounderline abstract_t">Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015; 314:884.</a></li><li><a class="nounderline abstract_t">Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219.</a></li><li><a class="nounderline abstract_t">Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385:2252.</a></li><li><a class="nounderline abstract_t">Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43:474.</a></li><li><a class="nounderline abstract_t">Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol 2020; 15:1715.</a></li><li><a class="nounderline abstract_t">Ito S, Shikata K, Nangaku M, et al. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Clin J Am Soc Nephrol 2019; 14:1161.</a></li><li><a class="nounderline abstract_t">Ito S, Itoh H, Rakugi H, et al. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension 2020; 75:51.</a></li><li><a class="nounderline abstract_t">Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394:131.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321:69.</a></li><li><a class="nounderline abstract_t">Cornel JH, Bakris GL, Stevens SR, et al. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care 2016; 39:2304.</a></li><li><a class="nounderline abstract_t">Wexler DJ, de Boer IH, Ghosh A, et al. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med 2023; 183:705.</a></li><li><a class="nounderline abstract_t">Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62:220.</a></li><li><a class="nounderline abstract_t">Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.</a></li><li><a class="nounderline abstract_t">Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2:1411.</a></li><li><a class="nounderline abstract_t">Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 2015; 26:220.</a></li><li><a class="nounderline abstract_t">Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365:327.</a></li><li><a class="nounderline abstract_t">de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492.</a></li><li><a class="nounderline abstract_t">Perkins RM, Aboudara MC, Uy AL, et al. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009; 53:606.</a></li><li><a class="nounderline abstract_t">Goicoechea M, García de Vinuesa S, Quiroga B, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 2012; 25:969.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393:1937.</a></li><li><a class="nounderline abstract_t">Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45:485.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686.</a></li><li><a class="nounderline abstract_t">Rossing P, Hansen BV, Nielsen FS, et al. Fish oil in diabetic nephropathy. Diabetes Care 1996; 19:1214.</a></li><li><a class="nounderline abstract_t">Hagiwara S, Makita Y, Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant 2006; 21:605.</a></li><li><a class="nounderline abstract_t">Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23:1946.</a></li><li><a class="nounderline abstract_t">Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20:655.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23:131.</a></li><li><a class="nounderline abstract_t">Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23:123.</a></li><li><a class="nounderline abstract_t">Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527.</a></li><li><a class="nounderline abstract_t">Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22:763.</a></li><li><a class="nounderline abstract_t">Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2:631.</a></li><li><a class="nounderline abstract_t">Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012; 60:896.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Brosius FC 3rd, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol Dial Transplant 2018; 33:1950.</a></li><li><a class="nounderline abstract_t">Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020; 97:42.</a></li><li><a class="nounderline abstract_t">Bakris GL, Weir MR. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. Am J Nephrol 2022; 53:513.</a></li><li><a class="nounderline abstract_t">Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.</a></li><li><a class="nounderline abstract_t">Collard D, Brouwer TF, Peters RJG, et al. Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. Hypertension 2018; 72:1337.</a></li><li><a class="nounderline abstract_t">Malhotra R, Craven T, Ambrosius WT, et al. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. Am J Kidney Dis 2019; 73:21.</a></li><li><a class="nounderline abstract_t">Cheung AK, Chang TI, Cushman WC, et al. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:1027.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S29.</a></li><li><a class="nounderline abstract_t">Ohkuma T, Jun M, Rodgers A, et al. Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension 2019; 73:84.</a></li><li><a class="nounderline abstract_t">Bhandari S, Mehta S, Khwaja A, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 2022; 387:2021.</a></li></ol></div><div id="topicVersionRevision">Topic 3052 Version 79.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.usrds.org/reference.aspx" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://www.usrds.org/reference.aspx (Accessed on March 05, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052124" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077236" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526393" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654536" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reversal of lesions of diabetic nephropathy after pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7643540" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24214280" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667706" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305006" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305751" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypoglycemia, chronic kidney disease, and diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358424" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Noninsulin glucose-lowering agents for the treatment of patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413456" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700028" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416309" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422755" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565517" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930097" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120823" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765963" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765962" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vascular outcome in type 2 diabetes: an ADVANCE?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316758" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378520" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Telmisartan, ramipril, or both in patients at high risk for vascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707986" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206457" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Combined angiotensin inhibition for the treatment of diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23249829" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121378" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cardiorenal end points in a trial of aliskiren for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862754" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33441402" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370424" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33214130" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34215025" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33302723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32998798" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36202661" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272755" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470878" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735306" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495651" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30424892" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27539604" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299675" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30314978" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200891" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33214158" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of Canagliflozin in Patients with Baseline eGFR&lt;30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970396" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dapagliflozin in Patients with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36331190" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Empagliflozin in Patients with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36351458" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24943000" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378978" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23895803" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120497" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605608" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29937267" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526832" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31196815" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415602" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865377" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31060053" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31133455" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33099609" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26325557" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264825" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34449181" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35023547" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33239409" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248950" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31786983" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854085" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Liraglutide and Renal Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29910024" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189509" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418475" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742728" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37213109" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081581" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984187" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574360" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Restriction of dietary protein and progression of renal failure in diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970885" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699484" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Bardoxolone methyl and kidney function in CKD with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206459" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19216016" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241639" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995972" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15754270" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249540" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The effect of ruboxistaurin on nephropathy in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8908382" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fish oil in diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282336" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18089623" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144760" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Avosentan reduces albumin excretion in diabetics with macroalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034637" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pyridorin in type 2 diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034636" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167702" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Avosentan for overt diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372210" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699475" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22770926" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481660" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31706619" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35691290" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724055" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571235" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291012" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010478" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559229" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571562" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36326117" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
